About
According to the Centers for Disease Control and Prevention, cardiovascular disease is the leading cause of death in the United States. The aging population, increase in obesity and cardiometabolic disease, ongoing health disparities and the suboptimal control of risk factors will likely exacerbate the incidence of cardiovascular disease in future years. This cardiovascular disease prevention conference will educate physicians, advanced care providers and the broader healthcare team on current guidelines and opinion on the identification of risk factors, prevention measures and treatment options for cardiovascular disease.
Registration Fees
In-Person General Admission: $100.00
Webinar Admission: $50.00
In-Person Industry Admission: $150.00
May 14, 2026: 5:30pm - 8:30pm CT
Southview Country Club
239 Mendota Rd E
West St Paul, MN 55118
United States
Meet the Faculty
Agenda
Accreditation
Primary Care, Internal Medicine, Family Medicine, OB/GYN and Cardiology Physicians, Advanced Practice Providers (Nurse Practitioner and Physician Assistants) and other health care professionals on their care teams
Allina Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Allina Health designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Allina Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Allina Health designates this live activity for 2.0 continuing education (CE) hours.
1. Describe recent updates to blood pressure management guidelines and evaluate how emerging wearable technologies can support hypertension monitoring and care.
2. Explain how to interpret coronary artery calcium scores.
3. Discuss emerging imaging strategies that will enhance cardiovascular risk assessment.
4. Describe how the menopause transition influences cardiometabolic risk in women.
5. Apply evidence-based approaches to manage CVD risk during and after the menopause transition, including hormone replacement therapy.
Thank you sponsors!
Alnylam
Amgen Cardiovascular
Bayer HealthCare
Boston Scientific
BridgeBio
Cleerly Health
Edwards Lifesciences
Invitae/Labcorp Genetics
IONIS
Kiniksa
Merck Vaccines
Novartis
Pfizer
Regeneron Pharmaceuticals
United Therapeutics